Results 191 to 200 of about 776,272 (319)
Rheumatoid arthritis is a disease characterized by joint inflammation. Approximately 50% of patients show insufficient response to traditional synthetic disease‐modifying antirheumatic drugs. This study aims to elucidate differential molecular profiles of the mechanisms underlying drug responses through multi‐omics strategy.
Congcong Jian +26 more
wiley +1 more source
Seropositive rheumatoid arthritis in osteogenesis imperfecta type XI (FKBP10 mutation): first case report and literature review. [PDF]
Manhal A +6 more
europepmc +1 more source
Biocatalytic Nanoregulators Restore Joint Redox‐Immune Homeostasis in Rheumatoid Arthritis
Mesenchymal stem cell‐derived extracellular vesicles (EVs) coat ruthenium‐loaded metal‐organic frameworks (Ru@ZrMOF), creating a targeted therapeutic (Ru@ZrMOF/EVs). This platform scavenges ROS, generates oxygen, and polarizes macrophages from M1 to M2, alleviating inflammation, inhibiting pannus, promoting cartilage repair, and downregulating HIF‐1α ...
Xingheng Wang +7 more
wiley +1 more source
Impact of Variation in APOE on Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Sequencing and Genotyping in General Population Cohorts. [PDF]
Rasmussen KL +5 more
europepmc +1 more source
Assessment of a New Test in Diagnosing Pediatric Septic Arthritis
Behnam Panjavi, Seyyed Hadi Kalantar
openalex +1 more source
Dysregulated Tissue resident macrophage (TRMs) link to autoimmune inflammation. SMURF2 mediates Lys‐27 (K27)‐linked ubiquitination of p‐TBK1 and its degradation, which inhibits CSF1R signaling‐triggered TRM proliferation, thereby restraining the autoimmune inflammation.
Xiang An +8 more
wiley +1 more source
Incidence of Pyogenic Arthritis in Aragón, Spain, From 2015 to 2023. [PDF]
San Pedro A +2 more
europepmc +1 more source
This study identifies CD74⁺ macrophages as key drivers of synovial inflammation in osteoarthritis (OA). The flavonoid luteolin is predicted to inhibit this pathway by blocking Nuclear Factor Kappa‐light‐chain‐enhancer of Activated B cells (NF‐κB) signaling. To enhance delivery, a targeted nanoplatform (MDSPL) is developed.
Rui Peng +15 more
wiley +1 more source

